Head of Research & Development Losan Pharma Neuenburg am Rhein, Baden-Wurttemberg, Germany
Liposomes have received renewed interest not least due to the successful application of lipid nanoparticle based delivery of mRNA vaccines in the context of Covid-19. However, liposome preparations are still lacking in scalability and encapsulation efficiency (EE). The developed one-pot-one-step process for the formation of Vesicular Phosholipid Gels (VPGs) which can be easily converted into nanosized liposomes with an Encapsulation Efficacy (EE) of more than 50% will be presented with two examples: the hydrophilic nonapeptide Leuprorelin Acetate and the model compound LP229719 representing a highly hydrophobic compound. Characterisation of the VPGs and corresponding Liposomes will be presented, their behavior in gastro biorelevant media and in-vivo results after oral application in rats. Finally, the toolbox will be described how to design and formulate these VPGs and nanosized liposomes dependent on the nature of the corresponding APIs.
Learning Objectives:
To understand the new technology and approach of preparation of nanoliposomes.
The participants get additional information of the suitability of the nanoliposome technology for the oral delivery of specific APIs and peptides.
To understand the design and different characterization techniques of the nanoliposomes.